The Medicines Company (NASDAQ:MDCO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
Stockholders on May 25, 2017 (the “Annual Meeting”). At the
Annual Meeting, the Company’s stockholders considered and voted on
the following proposals, each of which is described in more detail
in the 2017 Proxy Statement: (1) the election of eight class 1
directors for terms to expire at the Company’s 2018 annual meeting
of stockholders; (2) the approval, on an advisory basis, of the
compensation of the Company’s named executive officers as
presented in the 2017 Proxy Statement; (3) a proposal to vote, on
an advisory basis, on the frequency with which the Company’s
executive compensation will be subject to future advisory
stockholder votes; and (4) the ratification of the appointment of
Ernst Young LLP as the Company’s independent registered accounting
firm for the current fiscal year.
the matters described above, were as follows:
|
1.
|
The Company’s stockholders voted to elect the following
individuals as Class 1 directors of the Company, each for a one-year term expiring in 2018, or until their successors have been duly elected and qualified: |
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
William W. Crouse
|
60,558,410
|
1,388,189
|
98,215
|
3,496,077
|
|
Fredric N. Eshelman
|
61,779,886
|
253,770
|
11,158
|
3,496,077
|
|
Robert J. Hugin
|
57,015,507
|
4,929,207
|
100,100
|
3,496,077
|
|
John C. Kelly
|
61,762,834
|
184,535
|
97,445
|
3,496,077
|
|
Clive A. Meanwell
|
61,736,453
|
296,602
|
11,759
|
3,496,077
|
|
Paris Panayiotopoulos
|
61,959,113
|
77,562
|
8,139
|
3,496,077
|
|
Hiroaki Shigeta
|
61,654,581
|
289,324
|
100,909
|
3,496,077
|
|
Elizabeth H.S. Wyatt
|
61,656,566
|
288,290
|
99,958
|
3,496,077
|
|
2.
|
The Company’s executive compensation was approved, on an
advisory basis, based upon the following votes: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
61,405,916
|
528,630
|
110,268
|
3,496,077
|
|
3.
|
The Company’s stockholders voted, on an advisory basis, for
the Company to hold advisory votes on executive compensation on an annual basis, based upon the following votes: |
|
1 Year
|
2 Years
|
3 Years
|
Abstain
|
Broker Non-Votes
|
|
57,090,651
|
17,471
|
4,834,835
|
101,857
|
3,496,077
|
|
4.
|
The independent registered public accounting firm for the
current fiscal year was ratified based upon the following votes: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
65,345,285
|
191,747
|
3,859
|
About The Medicines Company (NASDAQ:MDCO)
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company’s products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic. The Medicines Company (NASDAQ:MDCO) Recent Trading Information
The Medicines Company (NASDAQ:MDCO) closed its last trading session up +2.01 at 39.77 with 3,099,174 shares trading hands.